Trial Profile
A Dose Response Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) But Not Well Controlled
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2015
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Amylin Pharmaceuticals; AstraZeneca
- 20 Dec 2007 Status changed from in progress to completed.
- 21 Oct 2006 New trial record.